Literature DB >> 10784593

Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats.

H Liu1, Z Ma, S S Lee.   

Abstract

BACKGROUND & AIMS: Decreased cardiac contractility and beta-adrenergic responsiveness have been observed in cirrhosis, but the etiology remains unclear. We aimed to test the role of nitric oxide (NO), a negative inotropic agent, in the pathogenesis of cirrhotic cardiomyopathy in a rat model.
METHODS: Cirrhosis was induced by bile duct ligation. Four weeks after ligation or sham operation, cardiac levels of tumor necrosis factor (TNF)-alpha, guanosine 3,5'-cyclic monophosphate (cGMP), inducible NOS (NOS2), and endothelial constitutive NOS (NOS3) messenger RNA (mRNA) and protein were determined. Serum nitrite/nitrate level was measured. Cardiac contractile function was evaluated in isolated left ventricular papillary muscles in the absence and presence of the NOS inhibitor nitro-L-arginine methyl ester (L-NAME).
RESULTS: Cardiac TNF-alpha, NOS2 mRNA and protein, cGMP, and serum interleukin (IL)-1beta and nitrite/nitrate levels were significantly higher in cirrhotic rats than sham controls. No significant differences in NOS3 mRNA or protein were found between cirrhotic and sham control rats. Baseline isoproterenol-stimulated papillary muscle contractile force was significantly lower in the cirrhotic group; with L-NAME incubation, contractile force increased significantly in cirrhotic rats but was unaffected in the controls. In normal papillary muscles, IL-1beta attenuated the contractility, but coincubation with L-NAME again reversed this attenuation. Incubation with the exogenous NO donor S-nitroso-N-acetyl-penicillamine also blunted papillary muscle contractility.
CONCLUSIONS: These results suggest that cytokine-induced stimulation of NOS2 plays a significant role in the pathogenesis of cirrhotic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10784593     DOI: 10.1016/s0016-5085(00)70180-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  39 in total

Review 1.  Cardiohepatic syndrome.

Authors:  Gerhard Poelzl; Johann Auer
Journal:  Curr Heart Fail Rep       Date:  2015-02

Review 2.  Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease.

Authors:  S Møller; J H Henriksen
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

3.  QT interval prolongation in end-stage liver disease cannot be explained by nonhepatic factors.

Authors:  Divyang Patel; Prabhpreet Singh; William Katz; Christopher Hughes; Kapil Chopra; Jan Němec
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-04-24       Impact factor: 1.468

Review 4.  Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients.

Authors:  Suehana Rahman; Susan V Mallett
Journal:  World J Hepatol       Date:  2015-03-27

5.  Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids.

Authors:  Ying-Ying Yang; Hongqun Liu; Soon Woo Nam; George Kunos; Samuel S Lee
Journal:  J Hepatol       Date:  2010-05-06       Impact factor: 25.083

Review 6.  Hepatosplanchnic circulation in cirrhosis and sepsis.

Authors:  Meghan Prin; Jan Bakker; Gebhard Wagener
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

Review 7.  Cirrhotic cardiomyopathy: a cardiologist's perspective.

Authors:  Natig Gassanov; Evren Caglayan; Nasser Semmo; Gero Massenkeil; Fikret Er
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 8.  Recent advances in cirrhotic cardiomyopathy.

Authors:  Dimitrios S Karagiannakis; George Papatheodoridis; Jiannis Vlachogiannakos
Journal:  Dig Dis Sci       Date:  2014-11-18       Impact factor: 3.199

Review 9.  Hydrogen sulphide and the hyperdynamic circulation in cirrhosis: a hypothesis.

Authors:  M R Ebrahimkhani; A R Mani; K Moore
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

10.  Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.

Authors:  J H Henriksen; J P Gøtze; S Fuglsang; E Christensen; F Bendtsen; S Møller
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.